DOCSLIB.ORG

Safety and Tolerability of Maximizing Oral Hypocholesterolemic Agents in Treating Severe FH

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Safety and Tolerability of Maximizing Oral Hypocholesterolemic Agents in Treating Severe FH Safety and Tolerability of Maximizing Oral Hypocholesterolemic Agents in Treating Severe FH Zuhier Awan, MD, PhD, FAACC, FRCPC, FAHA, FACE Consultant and Associate Professor of Medicine, Clinical Biochemistry and Molecular Genetic. Conflict of Interest Advisory Board, Speaker’s Bureau Pfizer Amgen Amryt (Aegerion) Outline Presentation 1. Tolerability of Lipid Lowering Drugs 2. Safety and Tolerability of Statin 3. Safety of Maximizing and Combining 18 Y student No medical illness Hx of premature CAD BMI 18 LDL 8 mmol/L Oral Lipid Lowering Drugs Patient Therapy TC LDL-C HDL-C TG Tolerability Statins* 19 – 37% 25 – 60% 4 – 12% 14 – 29% Good Ezetimibe 13% 18% 1% 9% Good Bile acid 7 – 10% 10 – 18% 3% Neutral or Poor sequestrants Nicotinic acid 10 – 20% 10 – 20% 14 – 35% 30 – 70% Reasonable to poor Fibrates 19% 4 – 8% 11 – 13% 30% Good *Daily dose of 40 mg of each drug, excluding rosuvastatin Yeshurun D et al. South Med J 1995;88:379–391. | NCEP. Circulation 1994;89:1333–1445. | Knopp RH. N Engl J Med 1999;341:498–511. | Gupta EK et al. Heart Dis 2002;4:399–409. Mechanism of Action LDL Fibrate apoB100 Liver X Statin X VLDL apoB100 Ezetimibe X Bile acid sequestrants X CM Remnant CM apoB48 apoB48 Oral Lipid Lowering Drugs Drug Class Agents Side Effects Drug Interaction HMG CoA Rosuvastatin (2C9) and Myopathy, Atorvastatin and Protease Inhibitor reductase Atorvastatin (3A4) increased liver Rosuvastatin and Colchicine inhibitors LDL (18-60) enzymes Simvastatin and Ketoconazole (Statins) Pitavastatin and Pravastatin LDL (30-50) Inhibitor of Ezetimibe Headache, GI Bile acid sequestrants (4 hours NPC1L1 LDL( 14-18) distress spacing) and Fibric acids (Ezetimibe) PPAR alpha Gemfibrozil Dyspepsia, Gemfibrozil and Atorvastatin agonist, Fenofibrate gallstones, hydrolyzes TG TG (20-50) myopathy in lipoproteins (Fibrates) Doses of Currently Available Statins Required for a 30% to 50% LDL-C Reduction Lipophilic (CYP 3A4) O HO O • 20–40 mg simvastatin (Zocor) 35–41% O HO O OH • 40 mg lovastatin (Mevacor) 31% OH • 10 mg atorvastatin (Lipitor) 39% CH F 3 CH3 Lipophilic (CYP 2C9) N F CH 3 CH3 • 40–80 mg fluvastatin (Lescol) 25–35% O N N HN N H3C S CH3 Hydrophilic O O • 5–10 mg rosuvastatin (Crestor) 39–45% • 40 mg pravastatin (Pravachol) 34% Grundy SM, et al. Circulation. 2004;110:227–239. Intensity of Statin Therapy High Moderate Low LDL-C ≥50% LDL-C 30 to <50% LDL-C <30% Atorva 40-80 mg Atorva 10 mg Simva 10 mg Rosuva 20-40 mg Rosuva 10 mg Prava 10-20 mg Simva 20-40 mg Lova 20 mg Pravas 40 mg Fluva 20-40 mg Lova 40 mg Pitava 1 mg Fluva XL 80 mg Fluva 40 mg bid Pitava 2-4 mg Statins in bold were evaluated in randomized controlled trials; those in italics were not 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults, p 34 Atorvastatin vs. Rosuvastatin Rosuvastatin Dosing Considerations in Specific Populations • Asians • May have higher blood concentrations and more risk of side effects than Caucasians • Start with 5 mg daily; maximum of 20 mg daily • Patients with renal impairment • Start with 5 mg daily; maximum of 10 mg daily • Patients who are predisposed to myopathy • Start with 5 mg daily Crestor® [package insert]; 2008. Statin Drug Interactions: Labeled Contraindications for Lovastatin and Simvastatin Lovastatin and simvastatin are contraindicated with: • Erythromycin • Cyclosporine • Clarithromycin • HIV protease • Fluconazole (2C9) inhibitors • Ketoconazole • Warfarin • Amidiodarone • Grapefruit juice HIV = human immunodeficiency virus Mevacor® [package insert]; 2008. | Zocor® [package insert]; 2008. FDA Warning (March 2010 + May 2011) • No Simvastatin with itraconazole, ketoconazole, erythromycin, clarithromycin, telithromycin, HIV protease inhibitors, or nefazodone. • No simvastatin >10 mg with gemfibrozil, cyclosporine, or danazol • No simvastatin >20 mg with amiodarone or verapamil • No simvastatin >40 mg with diltiazem • Patients of Chinese descent should not receive simvastatin 80 mg with cholesterol-modifying doses of niacin-containing products. • caution when such patients are treated with simvastatin 40 mg or less in combination with cholesterol-modifying doses of niacin-containing products 18 Y student No medical illness Hx of premature CAD BMI 18 LDL 8 mmol/L Outline Presentation 1. Tolerability of Lipid Lowering Drugs 2. Safety and Tolerability of Statin 3. Safety of Maximizing and Combining Question: How safe are statins? Statin Associated Muscle Symptoms SAMS MYALGIA Pain MYOPATHY Weakness MYOSITIS CK >10X ULN RHABDOMYOLYSIS CK >40X ULN Statin Safety in Perspective Number Needed to Treat: for 1 year to Cause a GI Bleed1 Cause a Fatal GI Bleed1 Aspirin 248 2066 Cause Severe Myositis2 Cause Fatal Myositis2 Statins 100 , 000 1,000,000 1Derry S, Loke YK. 2000 2Thompson PD, et al. 2003 Fatal Rhabodmyolysis Staffa JA, Chang J, Green L. Cerivastatin and reports of fatal rhabdomyolysis. N Engl J Med 2002; 346: 539-40 In Summary…The Risk is Small! 73 cases of fatal rhabdomyolysis in 484,273,000 Statin prescriptions In 2014: 15 – 20 million statin users only 3 deaths Staffa JA, Chang J, Green L. Cerivastatin and reports of fatal rhabdomyolysis. N Engl J Med 2002; 346: 539-40 US population: ± 300 million Peanut allergy 1.4% of population: 4.2 million affected 150 fatalities/year Question: Will patients tolerate statins? Muscle Related Side Effects Statins Intolerance No serial measurement of CK Journal of Clinical Lipidology (2014) 8, STOMP Study 420 healthy statin naïve subjects Atorvastatin 80 mg vs. Placebo 6 months Criculation 2013; 127: 96 - 103 The Effect of Statins on Skeletal Muscle Function and Performance (STOMP) study Atorvastatin 80 mg vs. placebo 6 MONTHS n=420 • Exercise capacity No significant changes • Muscle strength No significant changes • Myalgia 19 vs 10 (p=0.05) • CK ≥10 x ULN none Myalgic subjects on atorvastatin or placebo had decreased muscle strength in 5 of 14 and 4 of 14 variables, respectively (P=0.69). Circulation. 2013;127:96-103 The Effect of Statins on Skeletal Muscle Function and Performance (STOMP) study Circulation. 2013;127:96-103 Ann Intern Med. 2013;158:526-534. Discontinuation of Statins in Routine Care Statin use 2000 - 2008 Brigham's And Women's hospital Boston 120000 %120 107835 100000 %100 80000 %80 60000 57292 %60 40000 %40 18778 20000 %20 0 %0 patients discontinued documented events Ann Intern Med. 2013;158:526-534. Discontinuation of Statins in Routine Care Statin use 2000 - 2008 Brigham's And Women's hospital Boston 3000 2721 %120 Re-challenge in 6 579 patients 2500 93% were on statin after 12 months %100 2000 %80 1500 1295 %60 996 1000 %40 500 %20 0 %0 same statin same dosage higher dosage Ann Intern Med. 2013;158:526-534. Lesson Learned Statin Myalgia Clinical Index Score Region Time De-challenge Statin Myalgia Clinical Index Score Probable 9-11 Possible 7-8 Re-challenge Unlikely <7 Risk Factors for Statin-Associated Muscle Symptoms • Anthropometric • Concurrent conditions/medications • Surgery • Related history • Genetics (muscular dystrophy) • Other risk factors Evaluate Drug Interactions symptoms Follow-Up http://www.acc.org/StatinIntoleranceApp Hepatic Safety of Statins United Network for Organ Sharing (UNOS) Database • From 1990 – 2002 in the US: 51 741 liver transplants • 3 cases of acute liver failure related to statins* • 2 Cerivastatin • 1 Simvastatin • These studies were retrospective analyses. • Formal causality assessment of DILI and confirmation that cases were bona-fide cases of DILI from statins were not performed! * Russo MW, Galanko JA, Shrestha R, et al. Liver transplantation from drug induced liver injury in the United States. Liver Transpl 2004; 10:1018– 1023. Lancet 2010; 367: 1916-1922 Enzyme Activity During 3-year Follow-up in Patients with Raised Liver Enzymes Patients on statin treatment (n=227) Patients not statin treatment (n=210) Athyros, V. et al., Lancet 2010;376:1916-22. Cardiovascular Events in Patients with Normal and Abnormal LFT’s 12 63 (30%) of 210 117 (23%) of 510 patients patients 10 68% RRR 10% 23% RRR 8 P<0.0001 p<0001 patient patient years 7,6% 6 22 (10%) of 227 90 (14%) of 653 Statin patients patients 100 Control 4 4,6% 2 3,2% 0 Event rate Event / Abn LFT Norm LFT Athyros, V. et al., Lancet 2010;376:1916-22. Cardiovascular Events in Patients with Normal and Abnormal LFT’s 12 63 (30%) of 210 117 (23%) of 510 patients patients 10 68% RRR 10% 23% RRR 8 P<0.0001 p<0001 patient patient years 7,6% 6 22 (10%) of 227 90 (14%) of 653 Statin patients patients 100 Control 4 4,6% 2 3,2% 0 Event rate Event / Abn LFT Norm LFT Athyros, V. et al., Lancet 2010;376:1916-22. NAFLD at Baseline and Follow up Risk reduction of moderate to severe hepatic steatosis: 70% ! 36 44 27 35 27 32 Am J Gastroenterol advance online publication, Summary of studies using statin therapy for NAFLD F, fibrosis; CT, computed tomography; IN, inflammation; N / A, not applicable; NAFLD, nonalcoholic fatty liver disease; NASH, nonalcoholic steato hepatitis; RCT, randomized control trial; S, steatosis; US, ultrasound. Am J Gastroenterol advance online publication, Use of Atorvastatin or Pravastatin in Patients with NASH 5 patients with NASH 20 mg Prava for 6 months1 Normalization of liver enzymes in all patients Some improvement in hepatic inflammation and steatosis (liver biopsies) 7 patients with NASH 20 mg Atorvastatin 21 months (± 2 months)2 Well tolerated No increase in liver enzymes Significant improvement of hepatic histology in some patients 1. Rallidis LS, Drakoulis CK, Parasi AS. Pravastatin in patients with nonalcoholic steatohepatitis: results of a pilot study. Atherosclerosis 2004;174: 193-196. 2. Horlander JC, Kwo PY, Cummings OW. Atorvastatin for the treatment of NASH.
Load more

Recommended publications
  • Roszet (Rosuvastatin/Ezetimibe) – New Drug Approval
    Roszet (rosuvastatin/ezetimibe) – New drug approval • On March 23, 2021, the FDA approved Althera Pharmaceuticals’ Roszet (rosuvastatin/ezetimibe), in adults: as an adjunct to diet in patients with primary non-familial hyperlipidemia to reduce low- density lipoprotein cholesterol (LDL-C) and alone or as an adjunct to other LDL-C-lowering therapies in patients with homozygous familial hypercholesterolemia (HoFH) to reduce LDL-C. • Roszet is a combination tablet containing rosuvastatin, an HMG CoA-reductase inhibitor (statin), and ezetimibe, a dietary cholesterol absorption inhibitor. Both components are available generically. • The approval of Roszet was based on previous efficacy data with rosuvastatin and ezetimibe. • Roszet is contraindicated in patients with: — Acute liver failure or decompensated cirrhosis — Hypersensitivity to rosuvastatin, ezetimibe, or any excipients in Roszet. Hypersensitivity reactions including anaphylaxis, angioedema, and erythema multiforme have been reported. • Warnings and precautions for Roszet include myopathy and rhabdomyolysis, immune-mediated necrotizing myopathy, hepatic dysfunction, proteinuria and hematuria, and HbA1c and glucose levels. • The most common adverse reactions (> 2% and greater than statin alone) with ezetimibe co- administered with a statin are nasopharyngitis, myalgia, upper respiratory tract infection, arthralgia, diarrhea, back pain, influenza, pain in extremity, and fatigue. • The recommended dosage range of Roszet is 5 mg/10 mg to 40 mg/10 mg once daily. — The recommended dose of Roszet depends on a patient’s indication for usage, LDL-C, and individual risk for cardiovascular events. — The starting dosage for patients switching to Roszet from co-administration of a statin and ezetimibe is based on an equivalent dose of rosuvastatin and 10 mg of ezetimibe.
    [Show full text]
  • Effects of Pitavastatin, Atorvastatin, and Rosuvastatin on the Risk Of
    biomedicines Article Effects of Pitavastatin, Atorvastatin, and Rosuvastatin on the Risk of New-Onset Diabetes Mellitus: A Single-Center Cohort Study Wei-Ting Liu 1, Chin Lin 2,3,4, Min-Chien Tsai 5, Cheng-Chung Cheng 6, Sy-Jou Chen 7,8, Jun-Ting Liou 6 , Wei-Shiang Lin 6, Shu-Meng Cheng 6, Chin-Sheng Lin 6,* and Tien-Ping Tsao 6,9,* 1 Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei 11490, Taiwan; [email protected] 2 School of Public Health, National Defense Medical Center, Taipei 11490, Taiwan; [email protected] 3 School of Medicine, National Defense Medical Center, Taipei 11490, Taiwan 4 Graduate Institute of Life Sciences, National Defense Medical Center, Taipei 11490, Taiwan, 5 Department of Physiology and Biophysics, Graduate Institute of Physiology, National Defense Medical Center, Taipei 11490, Taiwan; [email protected] 6 Division of Cardiology, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei 11490, Taiwan; [email protected] (C.-C.C.); [email protected] (J.-T.L.); [email protected] (W.-S.L.); [email protected] (S.-M.C.) 7 Department of Emergency Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei 11490, Taiwan; [email protected] 8 Graduate Institute of Injury Prevention and Control, College of Public Health and Nutrition, Taipei Medical University, Taipei 11031, Taiwan 9 Division of Cardiology, Cheng Hsin General Hospital, Taipei 11220, Taiwan * Correspondence: [email protected] (C.-S.L.); [email protected] (T.-P.T.); Tel.: +886-2-6601-2656 (C.-S.L.); +886-2-2826-4400 (T.-P.T.) Received: 25 October 2020; Accepted: 11 November 2020; Published: 13 November 2020 Abstract: Statins constitute the mainstay treatment for atherosclerotic cardiovascular disease, which is associated with the risk of new-onset diabetes mellitus (NODM).
    [Show full text]
  • Nustendi, INN-Bempedoic Acid, Ezetimibe
    Summary of risk management plan for Nustendi (Bempedoic acid/Ezetimibe) This is a summary of the risk management plan (RMP) for Nustendi. The RMP details important risks of Nustendi, how these risks can be minimized, and how more information will be obtained about Nustendi's risks and uncertainties (missing information). Nustendi's summary of product characteristics (SmPC) and its package leaflet give essential information to healthcare professionals and patients on how Nustendi should be used. This summary of the RMP for Nustendi should be read in the context of all this information, including the assessment report of the evaluation and its plain-language summary, all which is part of the European Public Assessment Report (EPAR). Important new concerns or changes to the current ones will be included in updates of Nustendi's RMP. I. The Medicine and What It Is Used For Nustendi is authorized for treatment of primary hypercholesterolemia in adults, as an adjunct to diet (see SmPC for the full indication). It contains bempedoic acid as the active substance and it is given by mouth. Further information about the evaluation of Nustendi’s benefits can be found in Nustendi’s EPAR, including in its plain-language summary, available on the EMA website, under the medicine’s webpage https://www.ema.europa.eu/en/medicines/human/EPAR/nustendi II. Risks Associated With the Medicine and Activities to Minimize or Further Characterize the Risks Important risks of Nustendi, together with measures to minimize such risks and the proposed studies for learning
    [Show full text]
  • SUMMARY of the PRODUCT CHARACTERISTICS 1. NAME of the MEDICINAL PRODUCT <Invented Name> 10 Mg/10 Mg Film-Coated Tablets
    SUMMARY OF THE PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT <Invented name> 10 mg/10 mg film-coated tablets <Invented name> 20 mg/10 mg film-coated tablets <Invented name> 40 mg/10 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION <Invented name> 10 mg/10 mg: Each film-coated tablet contains 10 mg of rosuvastatin (as rosuvastatin calcium) and 10 mg of ezetimibe. <Invented name> 20 mg/10 mg: Each film-coated tablet contains 20 mg of rosuvastatin (as rosuvastatin calcium) and 10 mg of ezetimibe. <Invented name> 40 mg/10 mg: Each film-coated tablet contains 40 mg of rosuvastatin (as rosuvastatin calcium) and 10 mg of ezetimibe. Excipient with known effect: <Invented name> 10 mg/10 mg: Each film-coated tablet contains 111.2 mg of lactose (as lactose monohydrate). <Invented name> 20 mg/10 mg: Each film-coated tablet contains 168.6 mg of lactose (as lactose monohydrate). <Invented name> 40 mg/10 mg: Each film-coated tablet contains 286.0 mg of lactose (as lactose monohydrate). For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Film-coated tablet (tablet) <Invented name> 10 mg/10 mg: white to off-white oblong film-coated tablets. <Invented name> 20 mg/10 mg: yellow to light yellow oblong film-coated tablets. <Invented name> 40 mg/10 mg: pink oblong film-coated tablets. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Primary Hypercholesterolaemia/Homozygous Familial Hypercholesterolaemia (HoFH) <Invented name> is indicated for substitution therapy in adult patients who are adequately controlled with rosuvastatin and ezetimibe given concurrently at the same dose level as in the fixed combination, but as separate products, as adjunct to diet for treatment of primary hypercholesterolaemia (heterozygous familial and non-familial) or homozygous familial hypercholesterolaemia.
    [Show full text]
  • Product Monograph Crestor
    PRODUCT MONOGRAPH Pr CRESTOR® rosuvastatin calcium Tablets, 5, 10, 20 and 40 mg LIPID METABOLISM REGULATOR AstraZeneca Canada Inc. Date of Revision: May 14, 2020 1004 Middlegate Road Mississauga, Ontario L4Y 1M4 www.astrazeneca.ca Control No: 235939 CRESTOR® is a registered trademark of the AstraZeneca group of companies. Licensed from Shionogi & Co. Ltd. Osaka, Japan. COPYRIGHT 2003 – 2020 ASTRAZENECA CANADA INC. Page 1 of 46 TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION......................................................3 SUMMARY PRODUCT INFORMATION ..............................................................3 INDICATIONS AND CLINICAL USE....................................................................3 CONTRAINDICATIONS ........................................................................................4 WARNINGS AND PRECAUTIONS .......................................................................5 ADVERSE REACTIONS ...................................................................................... 10 DRUG INTERACTIONS....................................................................................... 16 DOSAGE AND ADMINISTRATION.................................................................... 22 OVERDOSAGE..................................................................................................... 25 ACTION AND CLINICAL PHARMACOLOGY................................................... 25 STORAGE AND STABILITY............................................................................... 27 DOSAGE
    [Show full text]
  • Bempedoic Acid) Tablets, for Oral Use Most Common (Incidence ≥ 2% and Greater Than Placebo) Adverse Reactions Initial U.S
    HIGHLIGHTS OF PRESCRIBING INFORMATION • Tendon Rupture: Tendon rupture has occurred. Discontinue NEXLETOL These highlights do not include all the information needed to use at the first sign of tendon rupture. Avoid NEXLETOL in patients who NEXLETOL™ safely and effectively. See full prescribing information have a history of tendon disorders or tendon rupture. (5.2) for NEXLETOL. --------------------------------ADVERSE REACTIONS----------------------------­ NEXLETOL (bempedoic acid) tablets, for oral use Most common (incidence ≥ 2% and greater than placebo) adverse reactions Initial U.S. Approval: 2020 are upper respiratory tract infection, muscle spasms, hyperuricemia, back pain, abdominal pain or discomfort, bronchitis, pain in extremity, anemia, ----------------------------INDICATIONS AND USAGE--------------------------­ and elevated liver enzymes. (6.1) NEXLETOL is an adenosine triphosphate-citrate lyase (ACL) inhibitor indicated as an adjunct to diet and maximally tolerated statin therapy for the To report SUSPECTED ADVERSE REACTIONS, contact Esperion at treatment of adults with heterozygous familial hypercholesterolemia or 833-377-7633 (833 ESPRMED) or FDA at 1-800-FDA-1088 or established atherosclerotic cardiovascular disease who require additional www.fda.gov/medwatch. lowering of LDL-C. (1) --------------------------------DRUG INTERACTIONS----------------------------­ Limitations of Use: The effect of NEXLETOL on cardiovascular morbidity • Simvastatin: Avoid concomitant use of NEXLETOL with simvastatin and mortality has not been
    [Show full text]
  • Rosuvastatin (Crestor)
    What is most important to remember? If you have questions: Strong Internal Medicine • Use this medicine as directed by your doctor Ask your doctor, nurse or pharmacist for more information about rosuvastatin • It is important to continue taking (Crestor®) this medicine even if you feel normal. Most people with high cholesterol or triglycerides do not feel sick • Do not start any new medicines, over-the-counter drugs or herbal remedies without talking to your doctor • Tell all doctors, dentists and pharmacists that you are using Strong Internal Medicine rosuvastatin (Crestor®) 601 Elmwood Avenue th • Contact your prescriber right away Ambulatory Care Facility, 5 Floor Rochester, NY 14642 if you have severe muscle pain or Phone: (585) 275 -7424 weakness Rosuvastatin Visit our website at: (Crestor®): • Follow the diet and lifestyle www.urmc.rochester.edu/medicine/ - genera medicine/patientcare/ Important Patient Information changes that you talked about l- with your doctor in addition to taking your prescribed medicine to get the greatest health benefits What does rosuvastatin (Crestor®) do? Who should know I am taking rosuvastatin (Crestor®)? What are some things that I need to be aware of when • It is used to lower the level of bad cholesterol (LDL), • Keep a list of all your medicines (prescription, natural taking rosuvastatin (Crestor®)? raise the level of good cholesterol (HDL), and lower products, supplements, vitamins, over-the-counter) and • Tell your doctor or pharmacist if you have a “statin” triglycerides (TG) in the body give
    [Show full text]
  • Efficacy of Combination Therapy of Rosuvastatin and Ezetimibe Vs
    Original Article DOI: 10.7860/JCDR/2017/30458.11004 Efficacy of Combination Therapy Internal Medicine Section of Rosuvastatin and Ezetimibe vs Rosuvastatin Monotherapy on Lipid Profile of Patients with Coronary Artery Disease SANDEEP JOSHI1, RUBY SHARMA2, HARBIR KAUR RAO3, UDIT NARANG4, NITIN GUPTA5 ABSTRACT baseline investigations and lifestyle modifications, Group I Introduction: Dyslipidaemia is one of the most important was started on rosuvastatin 10 mg once daily, while Group modifiable risk factor for the development of Coronary II was started on rosuvastatin 10 mg+ezetimibe 10 mg daily. Artery Disease (CAD). Although, statins are established as The fasting serum lipid profile was repeated initially after first line lipid-lowering therapy, they may not be able to 12 weeks and then after 24 weeks. The two groups were achieve treatment goals in significant number of patients. observed for side effects which were noted. Combination therapy of statin with a non-statin drug like Results: The combination therapy of rosuvastatin and Ezetimibe is a therapeutic option. ezetimibe resulted in significantly higher change in all Aim: To compare the efficacy and safety of Rosuvastatin/ lipid parameters (LDL-C, TC, TG, HDL-C) as compared to Ezetimibe combination therapy vs Rosuvastatin alone on the treatment with rosuvastatin alone. There was no difference in lipid profile of patients with CAD in Northern India. the adverse effects seen after treatment in the two groups. Materials and Methods: This randomized prospective Conclusion: Our study showed that combination therapy study was conducted on 80 patients of CAD presenting of ezetimibe with rosuvastatin can be used as an effective to Department of Medicine, Government Medical College, and safe therapy in high risk patients of CAD, especially in Patiala, Punjab, India.
    [Show full text]
  • CP.PMN.237 Bempedoic Acid (Nexletol)
    Clinical Policy: Bempedoic Acid (Nexletol), Bempedoic Acid/Ezetimibe (Nexlizet) Reference Number: CP.PMN.237 Effective Date: 09.01.20 Last Review Date: 02.21 Revision Log Line of Business: Commercial, HIM, Medicaid See Important Reminder at the end of this policy for important regulatory and legal information. Description The following are adenosine triphosphate-citrate lyase (ACL) inhibitors requiring prior authorization: bempedoic acid (Nexletol™) and bempedoic acid/ezetimibe (Nexlizet™). Nexlizet contains ezetimibe, which is a cholesterol absorption inhibitor. FDA Approved Indication(s) Nexletol and Nexlizet are indicated for use as adjuncts to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who require additional lowering of low-density lipoprotein cholesterol (LDL-C). Limitation(s) of use: The effect of Nexletol and Nexlizet on cardiovascular morbidity and mortality has not been determined. Policy/Criteria Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria. It is the policy of health plans affiliated with Centene Corporation® that Nexletol and Nexlizet are medically necessary when the following criteria are met: I. Initial Approval Criteria A. Heterozygous Familial Hypercholesterolemia and Atherosclerotic Cardiovascular Disease (must meet all): 1. Diagnosis of one of the following (a or b): a. ASCVD as evidenced by a history of any one of the following conditions (i-vii): i. Acute coronary syndromes; ii. Clinically significant coronary heart disease (CHD) diagnosed by invasive or noninvasive testing (such as coronary angiography, stress test using treadmill, stress echocardiography, or nuclear imaging); iii.
    [Show full text]
  • Rosuvastatin
    Rosuvastatin Rosuvastatin Systematic (IUPAC) name (3R,5S,6E)-7-[4-(4-fluorophenyl)-2-(N-methylmethanesulfonamido)-6-(propan- 2-yl)pyrimidin-5-yl]-3,5-dihydroxyhept-6-enoic acid Clinical data Trade names Crestor AHFS/Drugs.com monograph MedlinePlus a603033 Pregnancy AU: D category US: X (Contraindicated) Legal status AU: Prescription Only (S4) UK: Prescription-only (POM) US: ℞-only Routes of oral administration Pharmacokinetic data Bioavailability 20%[1] Protein binding 88%[1] Metabolism Liver (CYP2C9(major) andCYP2C19-mediated; only minimally (~10%) metabolised)[1] Biological half-life 19 hours[1] Excretion Faeces (90%)[1] Identifiers CAS Registry 287714-41-4 Number ATC code C10AA07 PubChem CID: 446157 IUPHAR/BPS 2954 DrugBank DB01098 UNII 413KH5ZJ73 KEGG D01915 ChEBI CHEBI:38545 ChEMBL CHEMBL1496 PDB ligand ID FBI (PDBe, RCSB PDB) Chemical data Formula C22H28FN3O6S Molecular mass 481.539 SMILES[show] InChI[show] (what is this?) (verify) Rosuvastatin (marketed by AstraZenecaas Crestor) 10 mg tablets Rosuvastatin, marketed as Crestor, is a member of the drug class of statins, used in combination with exercise, diet, and weight-loss to treat high cholesterol and related conditions, and to prevent cardiovascular disease. It was developed by Shionogi. Crestor is the fourth- highest selling drug in the United States, accounting for approx. $5.2 billion in sales in 2013.[2] Contents [hide] 1Medical uses 2Side effects and contraindications 3Drug interactions 4Structure 5Mechanism of action 6Pharmacokinetics 7Indications and regulation
    [Show full text]
  • Bempedoic Acid
    Drug and Biologic Coverage Policy Effective Date ............................................. 7/15/2020 Next Review Date ......................................... 7/1/2021 Coverage Policy Number .................................. 2015 Bempedoic acid Table of Contents Related Coverage Resources Coverage Policy ................................................... 1 Genetic Testing of Heritable Disorders FDA Approved Indications ................................... 4 Recommended Dosing ........................................ 4 General Background ............................................ 4 Coding/Billing Information .................................... 7 References .......................................................... 7 INSTRUCTIONS FOR USE The following Coverage Policy applies to health benefit plans administered by Cigna Companies. Certain Cigna Companies and/or lines of business only provide utilization review services to clients and do not make coverage determinations. References to standard benefit plan language and coverage determinations do not apply to those clients. Coverage Policies are intended to provide guidance in interpreting certain standard benefit plans administered by Cigna Companies. Please note, the terms of a customer’s particular benefit plan document [Group Service Agreement, Evidence of Coverage, Certificate of Coverage, Summary Plan Description (SPD) or similar plan document] may differ significantly from the standard benefit plans upon which these Coverage Policies are based. For example, a customer’s benefit
    [Show full text]
  • Rosuvastatin (Crestor®) VHA Pharmacy Benefits Management Strategic Healthcare Group and the Medical Advisory Panel
    National PBM-MAP Drug Monograph Rosuvastatin (Crestor®) VHA Pharmacy Benefits Management Strategic Healthcare Group and The Medical Advisory Panel Executive Summary Efficacy In 6 randomized, head-to-head statin comparative clinical trials, 10 mg of rosuvastatin resulted in a reduction in LDL-C of between 43-49%. The approximate equivalent daily dose of simvastatin and atorvastatin to rosuvastatin 10 mg are 80 mg and 40 mg, respectively. With regard to HDL-C elevation and triglyceride lowering, rosuvastatin produced changes similar to that seen with the other statins, with few exceptions. There are currently no published clinical trials demonstrating a reduction in health outcomes with rosuvastatin. Safety In pre-marketing controlled clinical trials, over 10,000 patients have been exposed to rosuvastatin. The most common adverse events included myalgia, constipation, asthenia, abdominal pain and nausea and were similar to those seen with other statins. Clinically significant elevation in liver function tests (LFTs, >3X upper limit of normal) was reported in 0-0.4% of patients receiving doses up to 40 mg daily. Clinically significant elevation in creatine kinase (CK, >10X upper limit of normal) was reported in 0.2-0.4% of patients taking up to 40 mg daily. Symptomatic myopathy, with significant elevation in CK, was reported in 0.1% of patients taking up to 40 mg of rosuvastatin daily. In the rosuvastatin clinical trials program, one case of rhabdomyolysis was reported with the 10 mg dose and 7 cases with the 80 mg dose. Rhabdomyolysis was not observed in pre-marketing clinical trials of other available statins. In the Stellar trial, 2 patients on rosuvastatin 80 mg per day developed renal failure of unknown etiology with one requiring short-term hemodialysis.
    [Show full text]